Who are sirolimus and oseltamivir's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sirolimus-and-oseltamivir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

sirolimus and oseltamivir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

sirolimus and oseltamivir (sirolimus and oseltamivir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mTOR inhibitor + neuraminidase inhibitor combination. Area: Infectious Disease / Virology.

phase 3 mTOR inhibitor + neuraminidase inhibitor combination mTOR (sirolimus); influenza neuraminidase (oseltamivir) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

sirolimus and oseltamivir (sirolimus and oseltamivir) — Chinese University of Hong Kong. This combination uses sirolimus (an mTOR inhibitor) to suppress immune responses and promote autophagy, while oseltamivir (a neuraminidase inhibitor) blocks viral replication of influenza.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sirolimus and oseltamivir TARGET	sirolimus and oseltamivir	Chinese University of Hong Kong	phase 3	mTOR inhibitor + neuraminidase inhibitor combination	mTOR (sirolimus); influenza neuraminidase (oseltamivir)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mTOR inhibitor + neuraminidase inhibitor combination class)

Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sirolimus and oseltamivir — Competitive Intelligence Brief. https://druglandscape.com/ci/sirolimus-and-oseltamivir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab